Autor |
Shinjo, Samuel Katsuyuki
![]() ![]() Bonfa, Eloisa ![]() Wojdyla, Daniel ![]() Borba, Eduardo F. ![]() Ramirez, Luis A. ![]() Scherbarth, Hugo R. ![]() Tavares Brenol, Joao C. ![]() Chacon-Diaz, Rosa ![]() Neira, Oscar J. ![]() Berbotto, Guillermo A. ![]() Garcia de La Torre, Ignacio ![]() Acevedo-Vazquez, Eduardo M. ![]() Massardo, Loreto ![]() Barile-Fabris, Leonor A. ![]() Caeiro, Francisco ![]() Silveira, Luis H. ![]() Sato, Emilia Inoue ![]() ![]() Buliubasich, Sandra ![]() Alarcon, Graciela S. ![]() Pons-Estel, Bernardo A. ![]() Grp Latino Amer Estudio Lupus Erit ![]() |
Instituição | Hosp Prov Rosario Universidade de São Paulo (USP) Univ Nacl Rosario Univ Antioquia Hosp Univ San Vicente de Paul Hosp Interzonal Gen Agudos Dr Oscar Alende Hosp Clin Porto Alegre Univ Fed Rio Grande do Sul Hosp Univ Caracas Hosp Salvador Univ Chile Hosp Escuela Eva Peron Hosp Gen Occidente Secretaria Salud Hosp Nacl Guillermo Almenara Irigoyen Pontificia Univ Catolica Chile Hosp Especialidades Ctr Med Nacl Siglo XXI Hosp Privado Inst Nacl Cardiol Ignacio Chavez Universidade Federal de São Paulo (UNIFESP) Hosp Nacl Clin Univ Alabama |
Resumo | Objective. To evaluate the beneficial effect of antimalarial treatment on lupus survival in a large, multiethnic, international longitudinal inception cohort.Methods. Socioeconomic and demographic characteristics, clinical manifestations, classification criteria, laboratory findings, and treatment variables were examined in patients with systemic lupus erythematosus (SLE) from the Grupo Latino Americano de Estudio del Lupus Eritematoso (GLADEL) cohort. the diagnosis of SLE, according to the American College of Rheumatology criteria, was assessed within 2 years of cohort entry. Cause of death was classified as active disease, infection, cardiovascular complications, thrombosis, malignancy, or other cause. Patients were subdivided by antimalarial use, grouped according to those who had received antimalarial drugs for at least 6 consecutive months (user) and those who had received antimalarial drugs for <6 consecutive months or who had never received antimalarial drugs (nonuser).Results. of the 1,480 patients included in the GLADEL cohort, 1,141 (77%) were considered antimalarial users, with a mean duration of drug exposure of 48.5 months (range 6-98 months). Death occurred in 89 patients (6.0%). A lower mortality rate was observed in antimalarial users compared with nonusers (4.4% versus 11.5%; P < 0.001). Seventy patients (6.1%) had received antimalarial drugs for 6-11 months, 146 (12.8%) for 1-2 years, and 925 (81.1%) for >2 years. Mortality rates among users by duration of antimalarial treatment (per 1,000 person-months of followup) were 3.85 (95% confidence interval [95% CI] 1.41-8.37), 2.7 (95% CI 1.41-4.76), and 0.54 (95% CI 0.37-0.77), respectively, while for nonusers, the mortality rate was 3.07 (95% CI 2.18-4.20) (P for trend < 0.001). After adjustment for potential confounders in a Cox regression model, antimalarial use was associated with a 38% reduction in the mortality rate (hazard ratio 0.62, 95% CI 0.39-0.99).Conclusion. Antimalarial drugs were shown to have a protective effect, possibly in a time-dependent manner, on SLE survival. These results suggest that the use of antimalarial treatment should be recommended for patients with lupus. |
Idioma | Inglês |
Financiador |
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Federico Wilhelm Agricola Foundation |
Número do financiamento |
|
Data | 2010-03-01 |
Publicado em | Arthritis and Rheumatism. Hoboken: Wiley-liss, v. 62, n. 3, p. 855-862, 2010. |
ISSN | 0004-3591 (Sherpa/Romeo, fator de impacto) |
Editor | Wiley-Blackwell |
Extensão | 855-862 |
Fonte |
|
Direito de acesso | Acesso aberto ![]() |
Tipo | Artigo |
Web of Science | WOS:000279432200026 |
URI | http://repositorio.unifesp.br/handle/11600/32277 |
Arquivos | Tamanho | Formato | Visualização |
---|---|---|---|
Não existem arquivos associados a este item. |